Modality
mRNA
MOA
KRASG12Di
Target
C5
Pathway
Autophagy
MyelofibrosisBCCMCC
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
~Dec 2021
→ ~Mar 2023
Phase 2
Jun 2023
→ Jun 2027
Phase 2Current
NCT04972664
2,350 pts·MCC
2023-06→2027-06·Recruiting
2,350 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-261.2y awayPh2 Data· MCC
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Recruit…
Catalysts
Ph2 Data
2027-06-26 · 1.2y away
MCC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04972664 | Phase 2 | MCC | Recruiting | 2350 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 |